Chi-Med mulls independent China development of new drugs
This article was originally published in Scrip
Executive Summary
A surge in partnership income last year has provided Hutchison China Medi-Tech (Chi-Med) with the financial wherewithal to consider bringing several of its in-house molecules to market by itself in China.